• Trailblazing Urothelial Cancer Treatments: Enfortumab Vedotin & Pembrolizumab

  • May 2 2024
  • Length: 18 mins
  • Podcast

Trailblazing Urothelial Cancer Treatments: Enfortumab Vedotin & Pembrolizumab

Listen for free

View show details

  • Summary

  • Shilpa Gupta, MD, Director of the Genitourinary Oncology Program at Cleveland Clinic Cancer Institute, provides an overview of the clinical trial of enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. Listen as Dr. Gupta talks about the exciting results of the trial, which showed that the combination therapy was effective for both cisplatin-eligible and cisplatin-ineligible patients. She also highlights the future studies that are being conducted to explore the use of the therapy in the neoadjuvant setting.
    Show more Show less
Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about Trailblazing Urothelial Cancer Treatments: Enfortumab Vedotin & Pembrolizumab

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available